ReviewMolecular cancer therapeutics2009
Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy.
Review in Molecular cancer therapeutics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 168 citations in OpenAlex.
- Article
- Genes and Longevity of Lifespan.International journal of molecular sciences · 2022Review
- Identification of Potential Kinase Inhibitors within the PI3K/AKT Pathway ofBiomolecules · 2021Article
- Progress Update in Pediatric Renal Tumors.Current oncology reports · 2021Review
- Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic.Cancer management and research · 2021Review
- Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression.Cell death & disease · 2019Article
- Role of PI3K/Akt and MEK/ERK Signalling in cAMP/Epac-Mediated Endothelial Barrier Stabilisation.Frontiers in physiology · 2019Article
- Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer.British journal of cancer · 2018Article
- Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity.ACS medicinal chemistry letters · 2017Article
- First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.Annals of oncology : official journal of the European Society for Medical Oncology · 2016Article
- Article
- Discovery of Novel and Orally Bioavailable Inhibitors of PI3 Kinase Based on Indazole Substituted Morpholino-Triazines.ACS medicinal chemistry letters · 2015Article
- Role of PI4K and PI3K-AKT in ERK1/2 activation by GnRH in the pituitary gonadotropes.Molecular and cellular endocrinology · 2015Article
- [Advances in leukemia inhibitors targeting PI3K/AKT/mTOR pathway].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015Article
- Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition.Molecular cancer therapeutics · 2015Article
- The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy.Oncotarget · 2015Article
- Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review.Journal of immunology research · 2015Review
- Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.Investigational new drugs · 2014Article
- Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast cancer cells.Breast cancer research : BCR · 2014Article
- Update on salvage options in relapsed/refractory hodgkin lymphoma after autotransplant.ISRN oncology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway is currently one of the most exciting drug targets in oncology. However, only a short time ago, the paradigm existed that drugs targeted to the four PI3K class I isoforms would be too toxic for use in cancer therapy due to effects on physiologic signaling. Since that time, studies have delineated the roles of these four isoforms in nonpathologic signaling as well as their roles in cancer. An extensive effort has gone into developing agents that inhibit one or more PI3K isoforms, as well as closely related proteins implicated in cancer. These agents have proved to be tolerable and therapeutically beneficial in animal studies, and a number are in clinical testing. The agents, their properties, and their molecular targets are discussed in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.